New Opportunities

[anonymous]

Sage took the same arrogant, ill thought out approach with the launch of the IV for PPD several years ago. And the launch failed miserably. Sounds as if no lessons were learned. Good luck to those of you who are in for round two.

It’s the same drug in a pill instead of a shot at a treatment clinic. Selling happiness is more profitable in a pill. If Purdue taught pharma anything, it’s better to take the patients out of the hospitals and let them self medicate. But for 5 figures, only rich miserable people will be able to afford it.

 

[anonymous]

Sagian here. You nailed it. But they get props for diversity and inclusion because that counts more these days than competence.

What diversity??

 

[anonymous]

Thankfully your days are numbered victim. We’re more than over listening to your drivel. Cry wolf more loser.

You should spend less time worrying about diversity so your lonely loser ass isn’t whining on the internet about it at 1 AM

 

[anonymous]

Can anyone speak to the culture under ADC in the north east? Hesitant to take the offer based off of her linkedin profile.

 

[anonymous]

Can anyone speak to the culture under ADC in the north east? Hesitant to take the offer based off of her linkedin profile.

hesitant because of her location LinkedIn profile. Why don’t you just reach out to some reps that have worked under her in the past and find out

 

[anonymous]

Very insightful response. I was recently notified on LinedIn that a former colleague of mine was recently hired here as a RSD somewhere in SoCal. MGraham is the epitome of a primary care mentality manager. His reputation precedes him - to any reps interviewing with that disaster… you’ve been warned. Get ready for Lazy Manager 101. Warning signs: he’ll talk up his “LTC experience at Shionogi (he was actually a Syneos contractor). Then he’ll talk about the “Lexapro days” when talking about contracting wins. Good luck expecting him to have your back once numbers don’t come in his favor. In summation: Sage picked up a pharma retread with no redeeming value. Will be watching vigilantly to see if there are any horror stories that pop up once he’s started his official reign of disappointment

And the woman who hired him hadn’t worked in two years so…